This proposal describes an innovative nutritional/pharmacological strategy to prevent proliferative retinopathy in a mouse model of disease with the expectation of a later clinical trial of patients with diabetic retinopathy (DR). DR has inflammatory and angiogenic components. We will evaluate alone and interactively the efficacy of the ?-3 long-chain polyunsaturated fatty acids (LCPUFAs) docosahexaenoic acid and eicosapentaenoic acid and Celecoxib, a selective cyclooxygenase (COX)-2 inhibitor, designed to target inflammatory and angiogenic factors implicated in the pathogenesis of proliferative DR. ?-3 LCPUFAs are concentrated in the retina and the status is modifiable by and dependent on dietary intake from foods that are not consumed in all Western diets, so these lipids are reasonable choices for interventions to prevent DR. Preliminary results show COX-2 inhibitors prevent ischemia-induced retinal neovascularization and that COX-2 inhibition is synergistic with ?-3 LCPUFAs. Should Celecoxib prove to cause cardiac disease we will switch to aspirin (COX 1,2 inhibition). To determine mechanism of inhibition and to determine complementary interventions, a new technique will be used to sensitively measure small changes with treatment in absolute copy number of mRNAs of specific lipid, inflammatory and angiogenic pathways involved in disease. The panel will include (but is not limited to) COX1,2, and LOX, vascular endothelial growth factor and receptors 1,2, cell adhesion molecules (ICAM-1, CD18), matrix metalloproteinases 2,9, cytokines (TNFa, TGF?), nuclear hormone receptor (NF?B), and nitric oxide synthetase. To assess intervention and possible new surrogate markers of DR we will assess retinal and blood levels of ?-3 LCPUFAs, arachidonic acid and eicosanoids (thromboxanes, prostaglandins, leukotrienes) in mice consuming balanced, isocaloric diets with, or without ?-3 LCPUFAs. For this translational work an inter-institutional and intra-disciplinary research group has been established with experts in the fields of molecular and cellular biology and angiogenesis (L Smith, (PI), D Carper, J-Y Tsai, NEI), clinical research (E Chew, J-P SanGiovanni, NEI), nutrition and lipid biochemistry (N Salem, NIAAA, C Serhan, Harvard). If successful, this work could have a great impact on preventing proliferative DR, as the interventions are safe, inexpensive, and can be easily implemented. Preliminary results show that COX-2 inhibitors, ?-3 LCPUFAs and combination inhibit retinopathy. These studies are innovative in that: 1. they are the first to examine the effect of LCPUFAs with or without COX-2 inhibitors on DR. 2. a new technique of finding absolute copy numbers of mRNA during disease and intervention allows comparison of interventions to evaluate complementary treatments. 3. lipid analysis may yield mechanism as well as new surrogate markers of DR and risk. ? ?

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
1R01EY017017-01
Application #
7013914
Study Section
Biology and Diseases of the Posterior Eye Study Section (BDPE)
Program Officer
Shen, Grace L
Project Start
2006-07-01
Project End
2011-06-30
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
1
Fiscal Year
2006
Total Cost
$602,113
Indirect Cost
Name
Children's Hospital Boston
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Hård, Anna-Lena; Nilsson, Anders K; Lund, Anna-My et al. (2018) Review shows that donor milk does not promote the growth and development of preterm infants as well as maternal milk. Acta Paediatr :
Hellgren, Gunnel; Löfqvist, Chatarina; Hansen-Pupp, Ingrid et al. (2018) Increased postnatal concentrations of pro-inflammatory cytokines are associated with reduced IGF-I levels and retinopathy of prematurity. Growth Horm IGF Res 39:19-24
Lundgren, Pia; Athikarisamy, Sam E; Patole, Sanjay et al. (2018) Duration of anaemia during the first week of life is an independent risk factor for retinopathy of prematurity. Acta Paediatr 107:759-766
Smith, Lois E H; Hellström, Ann; Stahl, Andreas et al. (2018) Development of a Retinopathy of Prematurity Activity Scale and Clinical Outcome Measures for Use in Clinical Trials. JAMA Ophthalmol :
Fu, Zhongjie; Wang, Zhongxiao; Liu, Chi-Hsiu et al. (2018) Fibroblast Growth Factor 21 Protects Photoreceptor Function in Type 1 Diabetic Mice. Diabetes 67:974-985
Wallace, David K; Dean, Trevano W; Hartnett, Mary Elizabeth et al. (2018) A Dosing Study of Bevacizumab for Retinopathy of Prematurity: Late Recurrences and Additional Treatments. Ophthalmology 125:1961-1966
Sveinsdóttir, Kristbjörg; Ley, David; Hövel, Holger et al. (2018) Relation of Retinopathy of Prematurity to Brain Volumes at Term Equivalent Age and Developmental Outcome at 2 Years of Corrected Age in Very Preterm Infants. Neonatology 114:46-52
Joyal, Jean-Sébastien; Gantner, Marin L; Smith, Lois E H (2018) Retinal energy demands control vascular supply of the retina in development and disease: The role of neuronal lipid and glucose metabolism. Prog Retin Eye Res 64:131-156
Lundgren, Pia; Hellgren, Gunnel; Pivodic, Aldina et al. (2018) Erythropoietin serum levels, versus anaemia as risk factors for severe retinopathy of prematurity. Pediatr Res :
Nilsson, Anders K; Löfqvist, Chatarina; Najm, Svetlana et al. (2018) Long-chain polyunsaturated fatty acids decline rapidly in milk from mothers delivering extremely preterm indicating the need for supplementation. Acta Paediatr 107:1020-1027

Showing the most recent 10 out of 108 publications